Market sentiment improved last week after the de-escalation of political tension between the US and Iran, and the signing of its phase 1 trade deal between US and China. The semblance of clarity nudged investors to move back into riskier assets, pushing global equities to hit new highs.
In the news
- The domestic equity market failed to keep up with the pace of its global peers, and slid lower over the week as weaker CPO prices put pressure on the market.
- CPO prices were impacted after tensions between Malaysia and India led the India government to effectively halt palm oil imports from Malaysia.
- After an intense start of the year, markets found calm after the political tension between the US and Iran eased.
- Sentiment improved further when the US and China finally inked its phase 1 trade deal last week, after 3-years of tariff threats and negotiation talks.
- China’s New Economy Sectors were seen moving ahead of the broader indices, as gauged by the S&P New China Sectors Ex A Share Index. Capitalising on China’s economic transition, the index, which is tracked by the (0828EA), rose 1.4 % in MYR terms last week. (Read more about China’s New Economy Sectors here to learn about the sectors that are benefitting from the economic transition.)
- The performance the index was seen benefitting also from the strong performance of technology-related stocks, evident in the 1.6% gain in MYR terms of the NYSE FANG+ Index. The S&P New China Sectors Ex A Share Index holds major China-based tech companies like Alibaba Group Holdings, Tencent, and Baidu within its constituents.
- Electronic car maker, Tesla, hit an all-time-high in its stock price last week after posting a surprise 3Q profit, and strong 4Q deliveries that beat expectations supported by its production line in China.
- After a meteoric rise which has seen its share price gain 6.8% in USD last week to bring its YTD gains to 22.0% up till 17 Jan 2020, analysts believe that Tesla is now once of the most shorted company on the US stock market.
- As global economies focus on growing its electric cars segment, coupled with the shift in innovation in the technology sector, is it time to build a double long exposure in the NYSE FANG+ Index through (0830EA), or would it be time to take lead from the analysts and hedge some position through the (0831EA)?
In other economic news
- China’s economy recorded its economic growth at 6.1% - within the expected range it has set earlier in the year. This marked China’s slowest growth in 29 years as the economy faced trade tensions with the US.
- Other data flowing out of China was, however, encouraging, with industrial production beating analysts forecast (6.9% vs 5.9%).
- Export figures also grew by 7.6% in December, a large leap from the 1.3% contraction recoded in November.
- Retail sales grew by 8.0% in December, though unchanged from November, it had beat the forecasted 7.9%.
- Germany’s GDP growth dropped to a 6-year low (0.6% in 2019) as Europe’s largest economy faced challenges in its car industry. The manufacturing sector contracted by 3.6% last year.
- The broader EU’s industrial production also slowed to a 0.2% MoM, missing the 0.3% forecasted
- Over the same month, inter EU trades has also fell by 3.8%, whilst imports from its global partners slid 4.6%.
What to look out for ahead?
- Will the Bank of England look to cut interest rates at the end of this month after disappointing PMI numbers out of UK?
- The People’s Bank of China had already cut borrowing costs to boost economic activity – leading to new bank lending in China hitting a record USD 2.44 trillion in December.
- But with the weak PMI numbers, can we expect more stimulus from the PBoC? What does this mean for China’s equity markets?
- With little signs on how phase 2 of the US – China trade deal will go, should we be expecting more market volatility ahead?
- What does this mean for the China equity markets? Will there be opportunities to capitalise from the growth in China companies and start considering opportunities within the Hang Seng China Enterprises Index? The (0832EA) offers the opportunities to gain approximately 2X the exposure to the HSCEI Index.
- But if its volatility that you’re expecting, it might be time to look into hedging your position with the (0833EA), an ETF that provides you an inverse return to the Hang Seng China Enterprises Index. Alternatively, there is an opportunity to hedge your investment portfolio through the (0828EA), a physically-backed Gold ETF listed on Bursa, and traded in Ringgit.
A look at the performance of the TradePlus ETFs, and major global indices
Source: Affin Hwang AM as at 10 Jan 2020. Prices and returns are quoted in MYR terms, and reflects the closing NAV of the ETF.
Source: Bloomberg as at 17 January 2020. Returns are quoted in MYR terms.
Disclaimer: This article has been prepared by Affin Hwang Asset Management Berhad (hereinafter referred to as “Affin Hwang AM”) specific for its use, a specific target audience, and for discussion purposes only. All information contained within this presentation belongs to Affin Hwang AM and may not be copied, distributed or otherwise disseminated in whole or in part without written consent of Affin Hwang AM. The information contained in this presentation may include, but is not limited to opinions, analysis, forecasts, projections and expectations (collectively referred to as “Opinions”). Such information has been obtained from various sources including those in the public domain, are merely expressions of belief. Although this presentation has been prepared on the basis of information and/or Opinions that are believed to be correct at the time the presentation was prepared, Affin Hwang AM makes no expressed or implied warranty as to the accuracy and completeness of any such information and/or Opinions. As with any forms of financial products, the financial product mentioned herein (if any) carries with it various risks. Although attempts have been made to disclose all possible risks involved, the financial product may still be subject to inherent risk that may arise beyond our reasonable contemplation. The financial product may be wholly unsuited for you, if you are adverse to the risk arising out of and/or in connection with the financial product. Affin Hwang AM is not acting as an advisor or agent to any person to whom this presentation is directed. Such persons must make their own independent assessments of the contents of this presentation, should not treat such content as advice relating to legal, accounting, taxation or investment matters and should consult their own advisers. Affin Hwang AM and its affiliates may act as a principal and agent in any transaction contemplated by this presentation, or any other transaction connected with any such transaction, and may as a result earn brokerage, commission or other income. Nothing in this presentation is intended to be, or should be construed as an offer to buy or sell, or invitation to subscribe for, any securities. Neither Affin Hwang AM nor any of its directors, employees or representatives are to have any liability (including liability to any person by reason of negligence or negligent misstatement) from any statement, opinion, information or matter (expressed or implied) arising out of, contained in or derived from or any omission from this presentation, except liability under statute that cannot be excluded.
Warning Statement: A Prospectus is available for the TradePlus Shariah Gold Tracker and TradePlus S&P New China Tracker, while a Master Prospectus is available for the TradePlus NYSE® FANG+TM Daily (2x) Leveraged Tracker, TradePlus NYSE® FANG+TM Daily (-1x) Inverse Tracker, TradePlus HSCEI Daily (2x) Leveraged Tracker and TradePlus HSCEI Daily (-1x) Inverse Tracker (collectively known as the “TradePlus L&I ETFs”), and investors have the right to request a copy of it. Investors are advised to read and understand the contents of the Prospectus dated 28 November 2017 and Supplementary Prospectus dated 2 July 2019 (for TradePlus Shariah Gold Tracker), and Prospectus dated 15 January 2019 and Supplementary Prospectus dated 2 July 2019 (for TradePlus S&P New China Tracker), as well as the Master Prospectus dated 26 November 2019 (for the TradePlus L&I ETFs) before investing. The Prospectus / Supplementary Prospectus / Master Prospectus have been registered with the Securities Commission Malaysia, who takes no responsibility for its contents. An electronic copy of the Prospectus / Supplementary Prospectus / Master Prospectus can be obtained at Affin Hwang Asset Management Berhad’s website www.tradeplus.com.my. As with any forms of financial products, the financial products mentioned herein carries with them various risks. Investors are advised to consider the general and specific risks involved as stipulated in its Prospectus / Supplementary Prospectus / Master Prospectus before investing. There are also fees and charges involved when investing in these funds, and investors are advised to consider the fees and charges carefully before investing. The price of units and distribution payable, if any, may go down as well as up and past performance of the funds should not be taken as indicative of their future performance.
Licensing Disclosure Statement & Conditions: The "S&P New China Ex A-Shares Index" is a product of S&P Dow Jones Indices LLC, a division of S&P Global, or its affiliates (“SPDJI”) and has been licensed for use by Affin Hwang Asset Management Bhd. Standard & Poor’s® and S&P® are registered trademarks of Standard & Poor’s Financial Services LLC, a division of S&P Global (“S&P”); Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC (“Dow Jones”) and these trademarks have been licensed for use by SPDJI and sublicensed for certain purposes by Affin Hwang Asset Management Bhd. TradePlus S&P New China Tracker is not sponsored, endorsed, sold or promoted by SPDJI, Dow Jones, S&P, their respective affiliates and none of such parties make any representation regarding the advisability of investing in such product(s) nor do they have any liability for any errors, omissions, or interruptions of the S&P New China Ex A-Shares Index.
Licensing Disclosure Statement & Conditions: Source ICE Data Indices, LLC (“ICE Data”), is used with permission. “NYSE® FANG+™” is a service/trade mark of ICE Data Indices, LLC or its affiliates and has been licensed, along with the NYSE® FANG+™ Daily 2X Leveraged Index and NYSE® FANG+™ Daily 1x Inverse Index (“Indices”) for use by Affin Hwang Asset Management Berhad in connection with the TradePlus NYSE® FANG+™ Daily (2x) Leveraged Tracker and the TradePlus NYSE® FANG+™ Daily (-1x) Inverse Tracker (the “Product”). Neither Affin Hwang Asset Management Berhad nor the Product, as applicable, is sponsored, endorsed, sold or promoted by ICE Data Indices, LLC, its affiliates or its Third Party Suppliers (“ICE Data and its Suppliers”). ICE Data and its Suppliers make no representations or warranties regarding the advisability of investing in securities generally, in the Product particularly, or the ability of the Index to track general stock market performance. ICE Data’s only relationship to Affin Hwang Asset Management Berhad (“Licensee”) is the licensing of certain trademarks and trade names and the Index or components thereof. The Index is determined, composed and calculated by ICE Data without regard to the Licensee or the Product or its holders. ICE Data has no obligation to take the needs of the Licensee or the holder of the Product into consideration in determining, composing or calculating the Index. ICE Data is not responsible for and has not participated in the determination of the timing of, prices of, or quantities of the Product to be issued or in the determination or calculation of the equation by which the Product is to be priced, sold, purchased, or redeemed. Except for certain custom index calculation services, all information provided by ICE Data is general in nature and not tailored to the needs of Licensee or any other person, entity or group of persons. ICE Data has no obligation or liability in connection with the administration, marketing, or trading of the Product. ICE Data is not an investment advisor. Inclusion of a security within an index is not a recommendation by ICE Data to buy, sell, or hold such security, nor is it considered to be investment advice.
ICE DATA AND ITS SUPPLIERS DISCLAIM ANY AND ALL WARRANTIES AND REPRESENTATIONS, EXPRESS AND/OR IMPLIED, INCLUDING ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, INCLUDING THE INDICES, INDEX DATA AND ANY INFORMATION INCLUDED IN, RELATED TO, OR DERIVED THEREFROM (“INDEX DATA”). ICE DATA AND ITS SUPPLIERS SHALL NOT BE SUBJECT TO ANY DAMAGES OR LIABILITY WITH RESPECT TO THE ADEQUACY, ACCURACY, TIMELINESS OR COMPLETENESS OF THE INDICES AND THE INDEX DATA, WHICH ARE PROVIDED ON AN “AS IS” BASIS AND YOUR USE IS AT YOUR OWN RISK.